The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
NCT05127759 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2023-08-08
Summary
The purpose of this study was to assess efficacy, safety and PK in metastatic colorectal cancer (mCRC) given HLX208 (BRAF V600E inhibitor).
Conditions
Interventions
- DRUG
-
HLX208
HLX208 450mg bid po
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-23
- Primary Completion
- 2024-01-30
- Completion
- 2025-06-28
Countries
- China
Study Locations
More Related Trials
-
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
NCT05438108 ·Status: UNKNOWN ·Phase: PHASE2
-
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
NCT05074966 ·Status: UNKNOWN ·Phase: PHASE3
-
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
NCT03511963 ·Status: COMPLETED ·Phase: PHASE3
-
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
NCT04317599 ·Status: COMPLETED
-
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
NCT05799820 ·Status: UNKNOWN ·Phase: PHASE2
-
mXELOXIRI Combined With Molecular Targeted Drug in mCRC
NCT04160416 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Clinical Study of LTC004 in Patients With mCRC
NCT06384235 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
NCT00202774 ·Status: COMPLETED ·Phase: PHASE3
-
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
NCT04110093 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
NCT05818267 ·Status: RECRUITING ·Phase: NA
-
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
NCT03567629 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
NCT05584137 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
NCT04380103 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
NCT01319877 ·Status: COMPLETED
-
A Study of ES104 in Patients With Metastatic Colorectal Cancer
NCT05167448 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
NCT00755118 ·Status: TERMINATED ·Phase: PHASE2
-
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
NCT05970302 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
NCT04547166 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
NCT04718038 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT04854434 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
NCT03380689 ·Status: WITHDRAWN ·Phase: PHASE1
-
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
NCT03843853 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
NCT07229846 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
NCT00111774 ·Status: COMPLETED ·Phase: PHASE2
-
XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
NCT03511170 ·Status: UNKNOWN ·Phase: PHASE2